Copyright © 2021 Pharmascimed. All Rights Reserved.
Featured
- February 27, 2019
- 0
Yesterday - Tuesday 26th February - saw senators grilling CEOs of no less than seven pharma-giants on high prescription drug prices that are a burden on Medicare, Medicaid and millions...
Read more- February 25, 2019
- 0
Novartis has acquired rights to TQJ230 from Akcea Therapeutics, a novel cardiovascular drug that could become first-in-class and has the potential to treat million of patients. TQJ230 is based on the...
Read more- February 25, 2019
- 0
Roche and Spark Therapeutics have announced they are to enter a definitive merger agreement for Roche to fully acquire Spark for $4.3bn - the first company to gain approval for...
Read more- February 22, 2019
- 0
AbbVie and Voyager Therapeutics have entered into an exclusive global strategic collaboration and option agreement to develop and commercialise vectorised antibodies for the potential treatment of Parkinson's disease. The deal means that Voyager...
Read more- February 21, 2019
- 0
Novo Nordisk has received U.S. FDA approval for Esperoct (turoctocog alfa peg, N8-GP) for the treatment of children and adults with haemophilia A. Today's decision permits physicians to prescribe the drug for...
Read more- February 19, 2019
- 0
British biotech Gyroscope Therapeutics may have stumbled onto a gold mine if its new gene therapy for the most common form of blindness proves effective. The company is currently treating...
Read more- February 19, 2019
- 0
The U.S. FDA have granted priority reviews for Roche's cancer drug polatuzumab vedotin, as well as personalised medication entrectinib. The priority review for polatuzumab veodtin comes on the back of results...
Read more- February 19, 2019
- 0
A new government unit called 'NHSX' is to be created with the aim of bringing technology to every patient and clinician as well as speeding up the digital transformation of...
Read more- February 19, 2019
- 0
A report published by market access consultancy MAP BioPharma is pushing for the National Institute for Health and Care Excellence (NICE) to be more 'flexible' with its work with NHS...
Read more